Scroll

pregabalin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
gabamimetic agents	2255	148553-50-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pregabalin (S)-Pregabalin gabanext maxgalin lyrica pregabalin hydrochloride pregabalin HCl	A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA. Molecular weight: 159.23 Formula: C8H17NO2 CLOGP: -0.92 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 63.32 ALOGS: -1.15 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pregabalin
(S)-Pregabalin
gabanext
maxgalin
lyrica
pregabalin hydrochloride
pregabalin HCl

A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.

Molecular weight: 159.23
Formula: C8H17NO2
CLOGP: -0.92
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 63.32
ALOGS: -1.15
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	90 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	53.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	11.30 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 2004	FDA	PF PRISM CV
July 6, 2004	EMA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Withdrawal syndrome	1580.57	9.92	1073	314538	18924	63154487
Somnolence	1286.92	9.92	2781	312830	175904	62997507
Intentional product misuse	627.91	9.92	1104	314507	59813	63113598
Feeling abnormal	566.79	9.92	1824	313787	146568	63026843
Pemphigus	506.11	9.92	143	315468	183583	62989828
Maternal exposure during pregnancy	425.30	9.92	286	315325	219776	62953635
Glossodynia	394.56	9.92	198	315413	178678	62994733
Weight increased	380.77	9.92	2407	313204	258385	62915026
Drug dependence	362.94	9.92	524	315087	23959	63149452
Systemic lupus erythematosus	359.48	9.92	306	315305	208612	62964799

Showing 1 to 10 of 674 entries

Previous1 2 3 4 5…68Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	1149.06	10.60	1755	149938	97341	34707897
Somnolence	756.48	10.60	1559	150134	109557	34695681
Drug dependence	694.07	10.60	679	151014	23538	34781700
Withdrawal syndrome	662.63	10.60	498	151195	11957	34793281
Intentional product misuse	422.93	10.60	731	150962	44880	34760358
Miosis	384.44	10.60	324	151369	9211	34796027
Coma	370.93	10.60	691	151002	44987	34760251
Pain	345.48	10.60	1776	149917	202899	34602339
Drug use disorder	314.74	10.60	207	151486	3984	34801254
Overdose	250.18	10.60	916	150777	90143	34715095

Showing 1 to 10 of 475 entries

Previous1 2 3 4 5…48Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Withdrawal syndrome	2075.96	9.83	1413	389010	25441	79328524
Somnolence	1568.64	9.83	3551	386872	235430	79118535
Drug abuse	986.70	9.83	2345	388078	160346	79193619
Intentional product misuse	946.33	9.83	1683	388740	93482	79260483
Drug dependence	922.16	9.83	1067	389356	39702	79314263
Pain	752.94	9.83	5948	384475	697854	78656111
Feeling abnormal	622.15	9.83	1953	388470	157246	79196719
Gait disturbance	436.50	9.83	2092	388331	205414	79148551
Drug withdrawal syndrome	434.47	9.83	681	389742	34037	79319928
Coma	433.51	9.83	1278	389145	99371	79254594

Showing 1 to 10 of 848 entries

Previous1 2 3 4 5…85Next

FDA Adverse Event Reporting System (Pediatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Telangiectasia congenital	34.38	28.19	9	239	18	89526

Showing 1 to 1 of 1 entries

Previous1Next

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N02BF02	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Gabapentinoids
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:38215	calcium channel blockers
MeSH PA	D000700	Analgesics
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents

Showing 1 to 10 of 16 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Postherpetic neuralgia	indication	2177002
Generalized anxiety disorder	indication	21897009	DOID:14320
Partial seizure	indication	29753000
Fibromyalgia	indication	203082005	DOID:631
Peripheral neuropathic pain	indication	279981003
Diabetic peripheral neuropathy	indication	424736006
Central neuropathic pain	indication	1259040000
Partial Epilepsy Treatment Adjunct	indication
Suicidal thoughts	contraindication	6471006
Weight gain finding	contraindication	8943002

Showing 1 to 10 of 23 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.97	acidic
pKa2	10.4	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
165MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	10022447	Nov. 2, 2026	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
165MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	10022447	Nov. 2, 2026	TREATMENT OF POSTHERPETIC NEURALGIA
165MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	8945620	Nov. 2, 2026	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
165MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	8945620	Nov. 2, 2026	TREATMENT OF POSTHERPETIC NEURALGIA
330MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	10022447	Nov. 2, 2026	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
330MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	10022447	Nov. 2, 2026	TREATMENT OF POSTHERPETIC NEURALGIA
330MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	8945620	Nov. 2, 2026	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
330MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	8945620	Nov. 2, 2026	TREATMENT OF POSTHERPETIC NEURALGIA
82.5MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	10022447	Nov. 2, 2026	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
82.5MG	LYRICA CR	UPJOHN	N209501	Oct. 11, 2017	RX	TABLET, EXTENDED RELEASE	ORAL	10022447	Nov. 2, 2026	TREATMENT OF POSTHERPETIC NEURALGIA

Showing 1 to 10 of 12 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Voltage-dependent calcium channel subunit alpha-2/delta-1	Ion channel	P54289	CA2D1_HUMAN	MODULATOR	IC50	7.10	WOMBAT-PK	CHEMBL
Voltage-dependent calcium channel subunit alpha-2/delta-2	Ion channel	Q9NY47	CA2D2_HUMAN	MODULATOR	IC50	7.26	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Large neutral amino acids transporter small subunit 1	Transporter	Q01650	LAT1_HUMAN		IC50	3.80	WOMBAT-PK
Uncharacterized protein; Voltage-dependent calcium channel alpha-2 delta subunit	Ion channel		O77773_PIG		IC50	7.14	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
010083	NDDF
187832	RXNORM
19649	MMSL
4024924	VUID
4024924	VANDF
415159003	SNOMEDCT_US
415160008	SNOMEDCT_US
530085-00-8	SECONDARY_CAS_RN
5484	IUPHAR_LIGAND_ID
5486971	PUBCHEM_CID

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1012	CAPSULE	25 mg	ORAL	NDA	33 sections
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1013	CAPSULE	50 mg	ORAL	NDA	33 sections
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1014	CAPSULE	75 mg	ORAL	NDA	33 sections
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1015	CAPSULE	100 mg	ORAL	NDA	33 sections
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1016	CAPSULE	150 mg	ORAL	NDA	33 sections
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1017	CAPSULE	200 mg	ORAL	NDA	33 sections
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1018	CAPSULE	300 mg	ORAL	NDA	33 sections
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1019	CAPSULE	225 mg	ORAL	NDA	33 sections
Lyrica	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1020	SOLUTION	20 mg	ORAL	NDA	33 sections
Lyrica CR	HUMAN PRESCRIPTION DRUG LABEL	1	0071-1026	TABLET, FILM COATED, EXTENDED RELEASE	82.50 mg	ORAL	NDA	33 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next